Adjuvant pembrolizumab (AP) does not improve long-term cure vs surveillance + first-line ipilimumab/nivolumab (I/N) at recurrence in resected clear-cell renal cell carcinoma: a 3.36 million-patient Monte Carlo-based microsimulation (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1141eP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor
|
|
Kelvin Yan; Kelvin C. Yan
|